Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
31.80
+0.71 (2.28%)
At close: Aug 18, 2026, 4:00 PM EDT
31.80
0.00 (0.00%)
After-hours: Aug 18, 2026, 4:10 PM EDT

Damora Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
22.39.6910.512.691313.74
Research & Development
74.0526.886.423.7748.2138.49
Operating Expenses
96.3536.5616.936.4661.2152.23
Operating Income
-96.35-36.56-16.9-36.46-61.21-52.23
Interest & Investment Income
8.171.170.911.261.291.23
Currency Exchange Gain (Loss)
--0.080.02-0.2-1.070.32
EBT Excluding Unusual Items
-88.18-35.48-15.97-35.4-60.99-50.68
Merger & Restructuring Charges
---0.97-3.45--
Gain (Loss) on Sale of Investments
---0.070.43-0.64-1.07
Gain (Loss) on Sale of Assets
---0.06--
Pretax Income
-262.49-209.79-21.4-38.35-61.62-51.75
Income Tax Expense
0.340.050.04---
Net Income
-262.83-209.84-21.44-38.35-61.62-51.75
Preferred Dividends & Other Adjustments
-21.58-----
Net Income to Common
-241.25-209.84-21.44-38.35-61.62-51.75
Net Income Growth
------
Shares Outstanding (Basic)
2411111
Shares Outstanding (Diluted)
2411111
Shares Change
1814.32%17.79%8.87%4.58%0.58%452.45%
EPS (Basic)
-9.88-153.95-18.53-36.08-60.63-51.22
EPS (Diluted)
-9.88-153.95-18.53-36.08-60.63-51.22
EPS Growth
------
Free Cash Flow
-44.52-6.73-18.62-36.91-43.13-52.53
Free Cash Flow Per Share
-1.82-4.93-16.09-34.73-42.43-51.99
EBITDA
-96.33-36.54-16.88-36.19-61.17-52.21
D&A For EBITDA
0.020.020.020.270.040.02
EBIT
-96.35-36.56-16.9-36.46-61.21-52.23
SEC Filings: 10-K · 10-Q